Related Experiment Video

Updated: Feb 9, 2026

Isolation of F1-ATPase from the Parasitic Protist Trypanosoma brucei
08:44

Isolation of F1-ATPase from the Parasitic Protist Trypanosoma brucei

Published on: January 22, 2019

7.8K

The V-ATPase as a target for antifungal drugs

Yongqiang Zhang1, Rajini Rao

  • 1Department of Physiology, The Johns Hopkins University School of Medicine, 725 N. Wolfe Street, Baltimore, MD 21205, USA.

Current Protein & Peptide Science
|January 24, 2012
PubMed

Insights

Targeting the V-ATPase (vacuolar-type proton pump) offers a promising strategy against fungal infections. Inhibiting this essential enzyme disrupts fungal survival, virulence, and drug resistance, paving the way for new antifungal therapies.

Area of Science:

  • Biochemistry
  • Mycology
  • Pharmacology

Background:

  • The vacuolar-type proton pump (V-ATPase) is crucial for pathogenic fungi.
  • V-ATPase function is essential for fungal virulence, stress response, morphology, and homeostasis.
  • Fungal V-ATPase is a potential target for antifungal chemotherapy.

Purpose of the Study:

  • To review the role of V-ATPase in fungal pathogenicity.
  • To explore V-ATPase as a chemotherapeutic target.
  • To discuss novel strategies for targeting V-ATPase in antifungal drug development.

Main Methods:

  • Literature review of V-ATPase function in pathogenic fungi.
  • Analysis of V-ATPase's role in virulence and drug resistance.
  • Examination of V-ATPase as a target for azole antifungals and membrane-modulating compounds.

Main Results:

  • V-ATPase impairment leads to multidrug sensitivity and reduced virulence.
  • Azole antifungals indirectly target V-ATPase by inhibiting ergosterol biogenesis.
  • Ergosterol depletion affects vacuolar pH, V-ATPase activity, and fungal growth.
  • Membrane lipids like sphingolipids and cardiolipin are critical for V-ATPase function.

Conclusions:

  • Targeting V-ATPase, directly or indirectly, significantly impacts fungal viability and virulence.
  • Developing fungal-specific V-ATPase inhibitors or membrane-active compounds is warranted for antifungal chemotherapy.

More Related Videos

Whole Genome Sequencing of Candida glabrata for Detection of Markers of Antifungal Drug Resistance08:45

Whole Genome Sequencing of Candida glabrata for Detection of Markers of Antifungal Drug Resistance

Published on: December 28, 2017

14.2K
Candida albicans Biofilm Chip CaBChip for High-throughput Antifungal Drug Screening08:05

Candida albicans Biofilm Chip CaBChip for High-throughput Antifungal Drug Screening

Published on: July 18, 2012

14.2K

Related Concept Videos

FDA Approved Drugs: Changes to Approved Drugs01:26

FDA Approved Drugs: Changes to Approved Drugs

Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
273
Bioequivalence of Drugs: Drugs with Multiple Indications01:09

Bioequivalence of Drugs: Drugs with Multiple Indications

The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each...
162
Pharmacokinetics: Drug–Drug Interactions01:25

Pharmacokinetics: Drug–Drug Interactions

Drug interactions occur when the pharmacological effect of one drug is altered by another substance, either enhancing or diminishing its activity. The drug whose activity is altered is known as the object drug, and the substance causing the alteration is called the agent drug or the precipitant. The net effects of these interactions are mostly undesirable, leading to decreased effectiveness or increased adverse effects. In rare cases, interactions can be beneficial, such as the enhanced...
454
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
10.5K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.9K
Factors Influencing Drug Absorption: Drug Dissolution01:27

Factors Influencing Drug Absorption: Drug Dissolution

The pharmacokinetic journey of drugs from solid oral dosage forms into systemic circulation is multifaceted. It begins with disintegration, a prerequisite ensuring a solid dosage form's subdivision into minute particles. Dissolution occurs next as these granulated entities solubilize in gastrointestinal fluids. This solubilization is crucial for the succeeding stage, permeation, which describes the traversal of the drug across the intestinal membrane and its subsequent entry into the blood...
1.2K